Xenon Pharmaceuticals is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near ...
A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE). Shares have added about 9.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback